Piper Sandler Begins Coverage on Axcella Health (NASDAQ:AXLA)

Piper Sandler started coverage on shares of Axcella Health (NASDAQ:AXLA) in a research report sent to investors on Thursday morning, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $25.00 price objective on the stock.

Several other analysts also recently weighed in on AXLA. BTIG Research dropped their target price on Axcella Health from $28.00 to $16.00 and set a buy rating for the company in a research report on Thursday, July 9th. SVB Leerink cut their target price on shares of Axcella Health from $21.00 to $20.00 and set an outperform rating on the stock in a research note on Monday, May 18th. Zacks Investment Research cut shares of Axcella Health from a buy rating to a hold rating in a research report on Monday, July 20th. ValuEngine raised Axcella Health from a buy rating to a strong-buy rating in a research report on Thursday, May 14th. Finally, Wedbush initiated coverage on Axcella Health in a report on Wednesday, May 27th. They issued an outperform rating and a $28.00 target price for the company. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $18.40.

Shares of AXLA stock opened at $4.49 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.91 and a quick ratio of 10.91. Axcella Health has a twelve month low of $2.25 and a twelve month high of $8.81. The company’s 50-day moving average price is $5.03 and its 200-day moving average price is $4.59.

Axcella Health (NASDAQ:AXLA) last posted its earnings results on Monday, May 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.21. Equities research analysts forecast that Axcella Health will post -0.79 earnings per share for the current year.

In other news, Director David R. Epstein acquired 50,000 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were purchased at an average cost of $4.20 per share, for a total transaction of $210,000.00. Also, major shareholder Ventures Fund Iv L.P Flagship acquired 3,800,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was purchased at an average cost of $4.20 per share, for a total transaction of $15,960,000.00. The disclosure for this purchase can be found here. Corporate insiders own 10.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in shares of Axcella Health by 14.5% during the 1st quarter. BlackRock Inc. now owns 341,479 shares of the company’s stock worth $1,168,000 after purchasing an additional 43,339 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Axcella Health by 22.1% during the first quarter. Bank of New York Mellon Corp now owns 24,256 shares of the company’s stock worth $83,000 after buying an additional 4,388 shares in the last quarter. State Street Corp grew its position in Axcella Health by 102.2% during the first quarter. State Street Corp now owns 115,765 shares of the company’s stock worth $396,000 after buying an additional 58,506 shares during the period. Geode Capital Management LLC acquired a new position in Axcella Health during the fourth quarter worth about $155,000. Finally, UBS Group AG increased its holdings in Axcella Health by 1,168.2% in the fourth quarter. UBS Group AG now owns 19,073 shares of the company’s stock valued at $76,000 after buying an additional 17,569 shares in the last quarter. Institutional investors own 43.13% of the company’s stock.

About Axcella Health

There is no company description available for Axcella Health Inc

Recommended Story: What does a neutral rating on stocks mean?

Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.